Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

Chronic graft-versus-host disease (cGVHD) is a common complication of allogeneic stem-cell transplantation. Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, recently received FDA breakthrough therapy and orphan drug designation for the treatment of patients with cGVHD who did not respond to ≥1 lines of systemic therapy. This designation was based, in part, on prior data presented by Miklos and colleagues, in which ibrutinib was shown to achieve an overall response rate of 67% in patients with steroid relapsed/refractory cGVHD (Miklos. Blood. 2016).

In this phase 3, randomized, controlled, double-blind study, investigators seek to evaluate the 24-week response rate of ibrutinib versus placebo in combination with prednisone. Patients with newly diagnosed moderate or severe cGVHD will be randomized to receive either oral ibrutinib or placebo in combination with oral prednisone. Ibrutinib or placebo will be given until unacceptable toxicity, relapse of underlying disease, death, or the need for a new systemic treatment for progressive cGVHD. To be eligible for the study, patients must be aged ≥12 years, must require systemic treatment with corticosteroids, and must have no prior systemic treatment for cGVHD.

The study’s primary end point is response rate (complete or partial response) at 24 weeks. To count toward the numerator, response must occur in the absence of both new therapy for cGVHD and relapse/return of the underlying disease that was the indication for transplant. Secondary end points include corticosteroid dose reduction, withdrawal of all immunosuppressants at 48 weeks, overall survival, response rate at 48 weeks, and safety. Recruitment is planned for approximately 186 patients.

Miklos DB, et al. ASCO Abstract TPS7072.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2017
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME